| Literature DB >> 35966153 |
Purevsuren Losol1,2,3, Hee-Sun Park1, Woo-Jung Song4, Yu-Kyoung Hwang1,2, Sae-Hoon Kim1,2,3, John W Holloway5, Yoon-Seok Chang1,2,3.
Abstract
Individual studies have suggested that upper airway dysbiosis may be associated with asthma or its severity. We aimed to systematically review studies that evaluated upper airway bacterial microbiota in relation to asthma, compared to nonasthmatic controls. Searches used MEDLINE, Embase, and Web of Science Core Collection. Eligible studies included association between asthma and upper airway dysbiosis; assessment of composition and diversity of upper airway microbiota using 16S rRNA or metagenomic sequencing; upper airway samples from nose, nasopharynx, oropharynx or hypopharynx. Study quality was assessed and rated using the Newcastle-Ottawa scale. A total of 249 publications were identified; 17 in the final analysis (13 childhood asthma and 4 adult asthma). Microbiome richness was measured in 6 studies, species diversity in 12, and bacterial composition in 17. The quality of evidence was good and fair. The alpha-diversity was found to be higher in younger children with wheezing and asthma, while it was lower when asthmatic children had rhinitis or mite sensitization. In children, Proteobacteria and Firmicutes were higher in asthmatics compared to controls (7 studies), and Moraxella, Streptococcus, and Haemophilus were predominant in the bacterial community. In pooled analysis, nasal Streptococcus colonization was associated with the presence of wheezing at age 5 (p = 0.04). In adult patients with asthma, the abundance of Proteobacteria was elevated in the upper respiratory tract (3 studies). Nasal colonization of Corynebacterium was lower in asthmatics (2 studies). This study demonstrates the potential relationships between asthma and specific bacterial colonization in the upper airway in adult and children with asthma.Entities:
Keywords: Asthma; Dysbiosis; Microbiota; Upper airway; Wheezing
Year: 2022 PMID: 35966153 PMCID: PMC9353206 DOI: 10.5415/apallergy.2022.12.e32
Source DB: PubMed Journal: Asia Pac Allergy ISSN: 2233-8276
Fig. 1PRISMA (Preferred Reporting Items from Systematic Reviews and Meta-Analyses) figure demonstrating literature excluded and examined in systematic review.
Summary of studies investigating the association between upper airway microbiota and childhood asthma
| Study | Country | Participant (n) | Asthma definition | Wheezing & asthma rate | Age at sample collection | Sample | Bacterial sequence, region | Method | Confounding factors | Changes in diversity and richness |
|---|---|---|---|---|---|---|---|---|---|---|
| Powell et al., 2019 [ | UK | 98 | Physician diagnosed wheeze | 26.5% wheeze at 24 mo | 6 wk, 6, 9, 12, 18, and 24 mo | Oropharyngeal swab | 16S rRNA V3-V5 | Roche 454 pyrosequencing | Ethnicity, family history of atopy, presence of fever, use of antibiotics in the 4 wk prior to visit | Increased α-diversity ( |
| Ta et al., 2018 [ | Singapore | 122 | Symptom-based wheeze | 27.8% rhinitis with wheezing at first 18 mo | 3 wks, 3, 6, 9, 12, 15, and 18 mo | Nasal swab | 16S rRNA V3-V6 | Illumina HiSeq | Gender, family history of respiratory disease, presence of siblings, mode of delivery, use of intrapartum antibiotic prophylaxis, postnatal antibiotics and breastfeeding pattern | Decreased α-diversity ( |
| Cardenas et al., 2012 [ | Ecuador | 48 | Physician diagnosed | 50% early-onset wheezing | Once at age 10.2 mo (mean) | Oropharyngeal swab | 16S rRNA V3-V5 | Roche 454 pyrosequencing | NA | No changes in diversity and richness |
| Teo et al., 2018 [ | Australia | 244 | Questionnaire based | 10.6% early-sensitized children with wheezing at 5 yr | 2, 6, and 12 mo | Nasopharyngeal sample | 16S rRNA V4 | Illumina MiSeq | Gender and lower respiratory infection | NA |
| Teo et al., 2015 [ | Australia | 234 | Symptom-based | 28% wheezing at 5 yr | 7, 8 and 9 wks, and 2, 6, and 12 mo | Nasopharyngeal sample | 16S rRNA V4 | Illumina MiSeq | Gender, maternal and paternal history of atopic disease | NA |
| Thorsen et al., 2019 [ | Denmark | 644 | Symptoms-based | 22.7% asthma in the first 6 yr | 1 wk, 1, and 3 mo | Hypopharyngeal aspirate | 16S rRNA V4 | Illumina MiSeq | NA | At age 1 month: increased Shannon index |
| Toivonen et al., 2020 [ | Finland | 704 | Physician diagnosed and medication | 8% at age 7 yr | 2, 13 and 24 mo | Nasal swab | 16S rRNA V4 | Illumina MiSeq | Gender, siblings, parental asthma and child’s eczema by age 13 mo | No changes in α and β-diversity measures. |
| Tang et al., 2021 [ | USA | 285 | Physician diagnosed and medication | 6–63% asthma at age 6, 8, 11, 13, and 18 yr | 2, 4, 6, 9, 12, 18, and 24 mo | Nasopharyngeal sample | 16S rRNA V4 | Illumina MiSeq | Age, gender, and season | NA |
| Chiu et al., 2017 [ | Taiwan | 87 | Questionnaire based | 36.7% asthma | Once at ages 3–5 yr | Throat swab | 16S rRNA V3-V4 | Illumina MiSeq | Age, gender, maternal atopy, passive smoking, older siblings, and household income OR FDR-adjusted | Lower Chao1 ( |
| Kim et al., 2017 [ | Korea | 92 | Physician diagnosed | 33.6% asthma | Once at ages 7.1–8 (mean) | Nasopharyngeal swab | 16S rRNA V1-V3, whole metagenome | Roche 454 pyrosequencing, Illumina HiSeq | NA | No change in α-diversity. Increased β-diversity ( |
| Birzele et al., 2017 [ | Austria | 86 | Physician diagnosed, symptom and questionnaire based | 22.9% asthma | Once at ages 6–12 yr | Nasal swab | 16S rRNA V3-V5 | Roche 454 pyrosequencing | Farming | Decreased richness OR=0.63, |
| Depner et al., 2017 [ | Germany | 68 | Physician diagnosed, symptom and questionnaire based | 57.3% asthma | Once at ages 7–12 yr | Nasal swab | 16S rRNA V3-V5 | Roche 454 pyrosequencing | Farming | Lowered richness |
| Castro-Nallar et al., 2015 [ | USA | 14 | Physician diagnosed | 57.1% asthma | Once at 11–15 years (mean) | Nasal brush | Whole metagenome | HiSeq metagenome sequencing | NA | High richness and low evenness |
NA, not applicable; V, variable regions.
Summary of studies investigating the association between upper airway microbiota and adult asthma
| Study | Country | Participant (n) | Asthma definition | Asthma rate (%) | Age (yr) | Comorbidity | Sample | Bacterial sequence, region | Method | Changes in diversity and richness | Taxonomical changes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Durack et al., 2018 [ | USA | 45 | Lung function test | 48.8 | 27–45 | Rhinitis 55% | Nasal brushing | 16S rRNA V4 | Illumina MiSeq | No changes in α-diversity | Decreased |
| Fazlollahi et al., 2018 [ | USA | 72 | Physician diagnosed and self-report | 70.8 | 35.8 ± 16 | Rhinitis 70.5% | Nasal swab | 16S rRNA V3-V4 | Illumina MiSeq | Increased α-diversity (not significant) | Increased Bacteroidetes ( |
| Lee et al., 2019 [ | Korea | 80 | Physician diagnosis, symptom and lung test | 75 | 18–45, > 65 | NA | Nasopharyngeal swab | 16S rRNA V1-V3, whole metagenome | Roche 454 pyrosequencing, Illumina HiSeq | No changes in Shannon diversity | Increased Proteobacteria ( |
| Park et al., 2014 [ | Korea | 47 | Symptoms-based | 38.2 | 23–79 | NA | Oropharyngeal sample | 16S rRNA V1-V3 | Roche 454 pyrosequencing, | Shannon diversity decreased (2.4 ± 1) vs. control (3.5 ± 0.7) | Increased |
Summary of differences in the composition of the upper airway microbiota associated with childhood asthma
| Sample collection | Relative abundance | Sample | Actinobacteria | Bacteroidetes | Firmicutes | Proteobacteria |
|---|---|---|---|---|---|---|
| ≤ 24 months | Increased | Nasal/nasopharyngeal swab | Aerococcaceae [ | |||
| Oropharyngeal swab | Flavobacteriaceae [ | Neisseriaceae [ | ||||
| Decreased | Nasal/nasopharyngeal swab | Corynebacteriaceae [ | Staphylococcaceae [ | |||
| Oropharyngeal swab | Bacteroidales [ | Pasteurellaceae [ | ||||
| Porphyromonas [ | Lachnospiraceae [ | |||||
| > 24 months | Increased | Nasal/nasopharyngeal sample | ||||
| Throat swab | ||||||
| Decreased | Nasal swab | |||||
| Throat swab | ||||||
FDR, false discovery rate; HR, hazard ratio; OR, odds ratio.